Loading company…
Medeor Therapeutics develops cellular immunotherapy to help kidney transplant patients reduce their reliance on immunosuppressants.
Founded in 2012 and headquartered in South San Francisco, US, Medeor Therapeutics develops cellular immunotherapy for kidney transplant recipients, using mixed chimerism to support long-term organ survival without continuous immunosuppressant drugs. The approach originated from Stanford University research and is in a Phase 3 trial for HLA-matched living donor kidney transplants. The company has raised a total of USD 57.00 mn, including a USD 18.80 mn grant led by the California Institute for Regenerative Medicine. Giovanni Ferrara is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in